|1.||Eriksson, Ulf G: 14 articles (04/2012 - 02/2002)|
|2.||Eriksson, Bengt I: 8 articles (01/2006 - 02/2002)|
|3.||Elg, Margareta: 5 articles (04/2012 - 08/2002)|
|4.||Carlsson, Stefan: 5 articles (01/2007 - 08/2002)|
|5.||Gustafsson, D: 5 articles (10/2003 - 02/2001)|
|6.||Frison, Lars: 5 articles (02/2003 - 02/2002)|
|7.||Wåhlander, Karin: 4 articles (04/2012 - 08/2002)|
|8.||Ogren, Mats: 4 articles (01/2006 - 03/2002)|
|9.||Dahl, Ola E: 4 articles (01/2006 - 11/2002)|
|10.||Bylock, Anders: 4 articles (01/2006 - 02/2002)|
|1.||Renal Insufficiency (Renal Failure)
09/01/2005 - "While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h). "
07/15/2005 - "Melagatran is primarily eliminated by the kidneys and has not been studied clinically in patients with severe renal failure. "
08/01/2005 - "(8) There are few data on the patient subgroups most likely to receive melagatran-ximelagatran, namely patients over 75, underweight and overweight patients, and patients with renal failure. "
08/01/2005 - "Hence, a higher melagatran exposure is seen in patients with renal failure; ximelagatran is currently not recommended for patients with severe renal impairment (creatinine clearance of <30 mL/min) as these patients were not included in the clinical trial program. "
08/01/2007 - "We aimed to determine whether melagatran would be effective in preventing thrombus formation on heterotopically placed mechanical heart valves. "
07/15/2003 - "Large-scale clinical trials are under way to evaluate the utility of an orally active prodrug form of melagatran for prevention and treatment of venous and arterial thrombosis."
05/01/2005 - "[Effective thrombosis prophylaxis with melagatran]."
09/01/2003 - "In this vena cava thrombosis model, no enhanced antithrombotic effect was observed with melagatran given as a s.c. "
04/01/2002 - "Blood samples from the great cardiac vein and aorta were collected at baseline, during thrombus formation, throughout the t-PA+/-melagatran infusion and during the patency period, for analysis of CPU activity using a novel assay. "
08/01/2005 - "Preoperative initiation of melagatran was more effective than when prophylactic treatment was initiated postoperatively, and the lowest rates of bleeding were associated with a postoperative initiation of prophylaxis. "
03/01/2002 - "Bleeding complications occurred in the only patient who received melagatran 6 mg, and this dose-arm was discontinued. "
03/01/1999 - "At the dose levels studied, melagatran was well tolerated with no clinically significant bleeding problems, suggesting that melagatran could safely be given to patients suffering from DVT."
08/01/2007 - "Melagatran did not increase the risk of thromboembolism or bleeding. "
02/01/2001 - "In several animal models of thrombosis, the antithrombotic properties of melagatran have been demonstrated, without any increase in experimental bleeding. "
03/01/2002 - "Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies."
01/01/2004 - "Clinical studies have shown that melagatran/ximelagatran, without coagulation monitoring, is effective and well tolerated for the prevention of venous thromboembolism after hip replacement and knee replacement surgery. "
01/01/2004 - "Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery."
01/01/2003 - "The objective of this population analysis was to characterise the pharmacokinetics of melagatran and its effect on activated partial thromboplastin time (APTT), an ex vivo measure of coagulation time, in orthopaedic surgery patients sequentially receiving subcutaneous melagatran and oral ximelagatran as prophylaxis for venous thromboembolism. "
08/01/2002 - "A fixed subcutaneously given dose of Melagatran, followed by orally administered Ximelagatran is effective and well tolerated as prophylaxis against venous thromboembolism."
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
05/02/2005 - "Melagatran was also effective in the venous thrombosis model, whereas it showed an aggravation in the disseminated intravascular coagulation model at low but not high doses. "
04/01/2005 - "The pharmacokinetics of melagatran in patients with acute deep vein thrombosis was predictable after oral ximelagatran administration. "
09/01/2003 - "In a rat venous thrombosis model, animals were openly randomized to receive subcutaneously (s.c.) either vehicle (saline, cyclodextrin or poloxamer) or melagatran (0.5 microM/kg) dissolved in vehicle. "
08/01/2005 - "These trials showed no advantage of melagatran-ximelagatran in terms of clinical endpoints such as symptomatic deep venous thrombosis, pulmonary embolism, and death from all causes. "
08/15/2002 - "This study evaluated the pharmacokinetics, pharmacodynamics, and clinical effects of melagatran, the active form of ximelagatran, in patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE). "
|7.||Dalteparin (Dalteparin Sodium)
|10.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|1.||Knee Replacement Arthroplasty (Total Knee Replacement)
|2.||Hip Replacement Arthroplasty (Total Hip Replacement)
|4.||Angioplasty (Angioplasty, Transluminal)